SAN FRANCISCO--(BUSINESS WIRE)--Presidio Pharmaceuticals, Inc. announces today that internationally recognized virologist and antiviral drug discoverer Dr. Richard Colonno has joined the company as Chief Scientific Officer.
“Rich brings to Presidio over 25 years of experience in antiviral drug discovery and development. During his career he has been responsible for the discovery, preclinical development and clinical support of novel antiviral agents in a wide range of viral disease indications, especially HIV and viral hepatitis. Many of these agents received worldwide regulatory approval and have contributed to major advancements in the treatment of HIV and viral hepatitis around the globe,” said Dr. Omar K. Haffar, President and CEO of Presidio Pharmaceuticals. “With the addition of Rich to the management team, we have an exceptionally qualified and experienced scientist to advance our HIV and hepatitis programs forward as rapidly as possible.”
